Association of genes of protease-antiprotease balance pathway to lung function and emphysema subtypes

BMC Pulmonary Medicine

Ari Hirvonen²  Päivi Piirilä¹  Panu Oksa²  Tapio Vehmas²  Emmi Tiili²  Mari K Kukkonen² 

[1] Department of Clinical Physiology, Helsinki University Hospital, Helsinki, Finland;Finnish Institute of Occupational Health, Topeliuksenkatu 41 a A, FI-00250, Helsinki, Finland

关键词: Protease-antiprotease balance;    Genetics;    Lung function;    Emphysema;   

Others  :  1109840
DOI  :  10.1186/1471-2466-13-36

 received in 2012-11-14, accepted in 2013-05-29,  发布年份 2013

【 摘 要 】

Background

The imbalance between proteases and antiproteases has been proposed to participate to the pathogenesis of chronic obstructive pulmonary disease (COPD) and emphysema. Gene level variation in different metalloproteinases, metalloproteinase inhibitors, and cytokines affecting them may contribute to this imbalance and destruction of the lung parenchyma. We investigated whether polymorphisms in selected protease-antiprotease balance pathway genes predispose to different emphysema subtypes (centrilobular, paraseptal, panlobular, and bullae) and airflow limitation among Finnish construction workers.

Methods

Eleven single nucleotide polymorphisms (SNPs) from seven genes (GC: rs7041 and rs4588; MMP1: rs1799750; MMP9: rs3918242; MMP12: rs652438; TIMP2: rs2277698; TNF: rs1799724 and rs1800629; TGFB1: rs1800469, rs1800470, and rs2241718) were analyzed from 951 clinically and radiologically characterized construction workers. The genotype and haplotype data was compared to different emphysematous signs confirmed with high resolution computed tomography (HRCT), forced vital capacity (FVC), forced expiratory volume in one second (FEV₁), and maximal expiratory flow at 50% of FVC (MEF50) by using linear and logistic regression analyses, adjusted for potential confounders.

Results

The TIMP2 rs2277698 SNP was associated with overall (p = 0.022) and paraseptal (p = 0.010) emphysema, as well as with FEV₁/FVC ratio (p = 0.035) and MEF50 (p = 0.008). The TGFB1 rs2241718 and MMP9 rs3918242 SNPs were associated with centrilobular emphysema (p = 0.022 and p = 0.008), and the TNF rs1800629 SNP with paraseptal emphysema (p = 0.017). In stratified analysis, individuals with at least one TIMP2 rs2277698 or TNF rs1800629 variant allele were found to be at around two-fold risk for pathological paraseptal changes (OR 1.94, 95% CI 1.14-3.30; OR 2.10, 95% CI 1.24-3.56). On the contrary, the risk for pathological centrilobular changes was halved for individuals with at least one MMP9 rs3918242 (OR 0.51, 95% CI 0.30-0.86) or TGFB1 rs2241718 (OR 0.53, 95% CI 0.30-0.90) variant allele, or TGFB1 rs1800469-rs1800470 AT-haplotype (OR 0.55, 95% CI 0.33-0.93). MEF50, in turn, was significantly reduced among individuals with at least one TIMP2 rs2277698 variant allele (p = 0.011).

Conclusion

Our findings strengthen the hypothesis of the importance of protease-antiprotease balance in pathogenesis of emphysema and shed light on the aetiology of different emphysema subtypes by associating MMP9 and TGFB1 to centrilobular emphysema, and TIMP2 and TNF to paraseptal emphysema and/or airflow obstruction.

【 授权许可】

   
2013 Kukkonen et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Barnes PJ, Shapiro SD, Pauwels RA: Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003, 22:672-688.
• [2]Abboud RT, Vimalanathan S: Pathogenesis of COPD. Part I. The role of protease-antiprotease imbalance in emphysema. Int J Tuberc Lung Dis 2008, 12:361-367.
• [3]Tomashefski JF Jr, Crystal RG, Wiedemann HP, Mascha E, Stoller JK: The bronchopulmonary pathology of alpha-1 antitrypsin (AAT) deficiency: findings of the Death Review Committee of the national registry for individuals with Severe Deficiency of Alpha-1 Antitrypsin. Hum Pathol 2004, 35:1452-1461.
• [4]DeMeo D, Mariani T, Lange C, Lake S, Litonjua A, Celedon J, Reilly J, Chapman HA, Sparrow D, Spira A, et al.: The SERPINE2 gene is associated with chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006, 3:502.
• [5]Zhu G, Warren L, Aponte J, Gulsvik A, Bakke P, Anderson WH, Lomas DA, Silverman EK, Pillai SG: The SERPINE2 gene is associated with chronic obstructive pulmonary disease in two large populations. Am J Respir Crit Care Med 2007, 176:167-173.
• [6]Fujimoto K, Ikeda S, Arai T, Tanaka N, Kumasaka T, Ishii T, Kida K, Muramatsu M, Sawabe M: Polymorphism of SERPINE2 gene is associated with pulmonary emphysema in consecutive autopsy cases. BMC Med Genet 2010, 11:159. BioMed Central Full Text
• [7]Kim WJ, Hoffman E, Reilly J, Hersh C, Demeo D, Washko G, Silverman EK: Association of COPD candidate genes with computed tomography emphysema and airway phenotypes in severe COPD. Eur Respir J 2011, 37:39-43.
• [8]Kukkonen MK, Tiili E, Hämäläinen S, Vehmas T, Oksa P, Piirilä P, Hirvonen A: SERPINE2 haplotype as a risk factor for panlobular type of emphysema. BMC Med Genet 2011, 12:157. BioMed Central Full Text
• [9]D’Armiento J, Dalal SS, Okada Y, Berg RA, Chada K: Collagenase expression in the lungs of transgenic mice causes pulmonary emphysema. Cell 1992, 71:955-961.
• [10]Foronjy R, Nkyimbeng T, Wallace A, Thankachen J, Okada Y, Lemaitre V, D'Armiento J: Transgenic expression of matrix metalloproteinase-9 causes adult-onset emphysema in mice associated with the loss of alveolar elastin. Am J Physiol Lung Cell Mol Physiol 2008, 294:L1149-1157.
• [11]Hautamäki RD, Kobayashi DK, Senior RM, Shapiro SD: Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science 1997, 277:2002-2004.
• [12]Ito I, Nagai S, Handa T, Muro S, Hirai T, Tsukino M, Mishima M: Matrix metalloproteinase-9 promoter polymorphism associated with upper lung dominant emphysema. Am J Respir Crit Care Med 2005, 172:1378-1382.
• [13]Tesfaigzi Y, Myers OB, Stidley CA, Schwalm K, Picchi M, Crowell RE, Gilliland FD, Belinsky SA: Genotypes in matrix metalloproteinase 9 are a risk factor for COPD. Int J Chron Obstruct Pulmon Dis 2006, 1:267-278.
• [14]Haq I, Chappell S, Johnson SR, Lotya J, Daly L, Morgan K, Guetta-Baranes T, Roca J, Rabinovich R, Millar AB, et al.: Association of MMP-12 polymorphisms with severe and very severe COPD: a case control study of MMPs-1, 9 and 12 in a European population. BMC Med Genet 2010, 11:7.
• [15]Hunninghake GM, Cho MH, Tesfaigzi Y, Soto-Quiros ME, Avila L, Lasky-Su J, Stidley C, Melen E, Soderhall C, Hallberg J, et al.: MMP12, lung function, and COPD in high-risk populations. N Engl J Med 2009, 361:2599-2608.
• [16]Hirano K, Sakamoto T, Uchida Y, Morishima Y, Masuyama K, Ishii Y, Nomura A, Ohtsuka M, Sekizawa K: Tissue inhibitor of metalloproteinases-2 gene polymorphisms in chronic obstructive pulmonary disease. Eur Respir J 2001, 18:748-752.
• [17]Hegab AE, Sakamoto T, Uchida Y, Nomura A, Ishii Y, Morishima Y, Mochizuki M, Kimura T, Saitoh W, Kiwamoto T, et al.: Association analysis of tissue inhibitor of metalloproteinase2 gene polymorphisms with COPD in Egyptians. Respir Med 2005, 99:107-110.
• [18]Churg A, Wang RD, Tai H, Wang X, Xie C, Dai J, Shapiro SD, Wright JL: Macrophage metalloelastase mediates acute cigarette smoke-induced inflammation via tumor necrosis factor-alpha release. Am J Respir Crit Care Med 2003, 167:1083-1089.
• [19]Morris DG, Huang X, Kaminski N, Wang Y, Shapiro SD, Dolganov G, Glick A, Sheppard D: Loss of integrin alpha(v)beta6-mediated TGF-beta activation causes Mmp12-dependent emphysema. Nature 2003, 422:169-173.
• [20]Lundblad LK, Thompson-Figueroa J, Leclair T, Sullivan MJ, Poynter ME, Irvin CG, Bates JH: Tumor necrosis factor-alpha overexpression in lung disease: a single cause behind a complex phenotype. Am J Respir Crit Care Med 2005, 171:1363-1370.
• [21]Celedon JC, Lange C, Raby BA, Litonjua AA, Palmer LJ, DeMeo DL, Reilly JJ, Kwiatkowski DJ, Chapman HA, Laird N, et al.: The transforming growth factor-beta1 (TGFB1) gene is associated with chronic obstructive pulmonary disease (COPD). Hum Mol Genet 2004, 13:1649-1656.
• [22]Gingo MR, Silveira LJ, Miller YE, Friedlander AL, Cosgrove GP, Chan ED, Maier LA, Bowler RP: Tumour necrosis factor gene polymorphisms are associated with COPD. Eur Respir J 2008, 31:1005-1012.
• [23]Ito M, Hanaoka M, Droma Y, Hatayama O, Sato E, Katsuyama Y, Fujimoto K, Ota M: The association of transforming growth factor beta 1 gene polymorphisms with the emphysema phenotype of COPD in Japanese. Intern Med 2008, 47:1387-1394.
• [24]Cho MH, Washko GR, Hoffmann TJ, Criner GJ, Hoffman EA, Martinez FJ, Laird N, Reilly JJ, Silverman EK: Cluster analysis in severe emphysema subjects using phenotype and genotype data: an exploratory investigation. Respir Res 2010, 11:30. BioMed Central Full Text
• [25]Castaldi PJ, Cho MH, Cohn M, Langerman F, Moran S, Tarragona N, Moukhachen H, Venugopal R, Hasimja D, Kao E, et al.: The COPD genetic association compendium: a comprehensive online database of COPD genetic associations. Hum Mol Genet 2010, 19:526-534.
• [26]Zhang S, Wang C, Xi B, Li X: Association between the tumour necrosis factor-alpha-308G/A polymorphism and chronic obstructive pulmonary disease: an update. Respirology 2011, 16:107-115.
• [27]Janssens W, Lehouck A, Carremans C, Bouillon R, Mathieu C, Decramer M: Vitamin D beyond bones in chronic obstructive pulmonary disease: time to act. Am J Respir Crit Care Med 2009, 179:630-636.
• [28]Janssens W, Bouillon R, Claes B, Carremans C, Lehouck A, Buysschaert I, Coolen J, Mathieu C, Decramer M, Lambrechts D: Vitamin D deficiency is highly prevalent in COPD and correlates with variants in the vitamin D-binding gene. Thorax 2010, 65:215-220.
• [29]Wood AM, Bassford C, Webster D, Newby P, Rajesh P, Stockley RA, Thickett DR: Vitamin D-binding protein contributes to COPD by activation of alveolar macrophages. Thorax 2011, 66:205-210.
• [30]Huuskonen O, Kivisaari L, Zitting A, Kaleva S, Vehmas T: Emphysema findings associated with heavy asbestos-exposure in high resolution computed tomography of finnish construction workers. J Occup Health 2004, 46:266-271.
• [31]Piirilä P, Lindqvist M, Huuskonen O, Kaleva S, Koskinen H, Lehtola H, Vehmas T, Kivisaari L, Sovijärvi AR: Impairment of lung function in asbestos-exposed workers in relation to high-resolution computed tomography. Scand J Work Environ Health 2005, 31:44-51.
• [32]Vierikko T, Järvenpää R, Autti T, Oksa P, Huuskonen M, Kaleva S, Laurikka J, Kajander S, Paakkola K, Saarelainen S, et al.: Chest CT screening of asbestos-exposed workers: lung lesions and incidental findings. Eur Respir J 2007, 29:78-84.
• [33]Webb W, Müller N, Naidich D: High-resolution CT of the lung. 2nd edition. Philadelphia: Lippincott-Raven Publishers; 1996.
• [34]Viljanen AA: Reference values for spirometric, pulmonary diffusing capacity and body plethysmographic studies. Scand J Clin Invest Suppl 1982, 159:1-50.
• [35]Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC: Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993, 16:5-40.
• [36]Andreassen CN, Alsner J, Overgaard J, Herskind C, Haviland J, Owen R, Homewood J, Bliss J, Yarnold J: TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. Radiother Oncol 2005, 75:18-21.
• [37]Joos L, He JQ, Shepherdson MB, Connett JE, Anthonisen NR, Pare PD, Sandford AJ: The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function. Hum Mol Genet 2002, 11:569-576.
• [38]Ozen S, Alikasifoglu M, Bakkaloglu A, Duzova A, Jarosova K, Nemcova D, Besbas N, Vencovsky J, Tuncbilek E: Tumour necrosis factor alpha G– > A −238 and G– > A −308 polymorphisms in juvenile idiopathic arthritis. Rheumatology 2002, 41:223-227.
• [39]Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
• [40]Stephens M, Donnelly P: A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003, 73:1162-1169.
• [41]Lee SY, Kim MJ, Kang HG, Yoo SS, Choi YY, Lee WK, Cha SI, Kim CH, Jung TH, Park JY: Polymorphisms in matrix metalloproteinase-1, -9 and −12 genes and the risk of chronic obstructive pulmonary disease in a Korean population. Respiration 2010, 80:133-138.
• [42]Mocchegiani E, Giacconi R, Costarelli L: Metalloproteases/anti-metalloproteases imbalance in chronic obstructive pulmonary disease: genetic factors and treatment implications. Curr Opin Pulm Med Suppl 2011, 17:S11-19.
• [43]Finkelstein R, Ma HD, Ghezzo H, Whittaker K, Fraser RS, Cosio MG: Morphometry of small airways in smokers and its relationship to emphysema type and hyperresponsiveness. Am J Respir Crit Care Med 1995, 152:267-276.
• [44]Satoh K, Kobayashi T, Misao T, Hitani Y, Yamamoto Y, Nishiyama Y, Ohkawa M: CT assessment of subtypes of pulmonary emphysema in smokers. Chest 2001, 120:725-729.
• [45]Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, Van der Grinten CP, Gustafsson P, Hankinson J, et al.: Interpretative strategies for lung function tests. Eur Respir J 2005, 26:948-968.
• [46]Lee PH, Shatkay H: F-SNP: computationally predicted functional SNPs for disease association studies. Nucleic Acids Res 2008, 36:D820-824.
• [47]Kroeger KM, Carville KS, Abraham LJ: The −308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol 1997, 34:391-399.
• [48]Churg A, Wang RD, Tai H, Wang X, Xie C, Wright JL: Tumor necrosis factor-alpha drives 70% of cigarette smoke-induced emphysema in the mouse. Am J Respir Crit Care Med 2004, 170:492-498.
• [49]Rothman KJ: No adjustments are needed for multiple comparisons. Epidemiology 1990, 1:43-46.